导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.92% | 2449/4773 |
| 近一周 | -2.35% | 1899/5462 |
| 近一月 | -8.07% | 4088/5421 |
| 近一季 | 10.49% | 152/5209 |
| 近半年 | 1.67% | 1023/4920 |
| 近一年 | -12.87% | 3580/4366 |
| 近两年 | 25.40% | 2480/2954 |
| 近三年 | -2.68% | 1966/2253 |
| 成立以来 | 18.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.98% 2048/4961 |
-3.37% 3453/5312 |
- - |
- - |
| 2025 | 10.35% 2818/4813 |
2.53% 1347/3635 |
2.50% 1533/4076 |
19.08% 2190/4524 |
-11.82% 4216/4813 |
| 2024 | -11.50% 2356/3463 |
-12.14% 2448/2808 |
-8.87% 2298/3014 |
19.37% 851/3129 |
-7.39% 2755/3463 |
| 2023 | -9.86% 1240/2656 |
-0.72% 1822/2280 |
-7.30% 1830/2385 |
0.39% 370/2515 |
-2.43% 473/2655 |
| 2022 | -22.21% 1064/2207 |
-10.65% 409/1919 |
-2.27% 1771/2016 |
-18.79% 1735/2113 |
9.70% 200/2208 |
| 2021 | -13.29% 1135/1822 |
-3.08% 755/1255 |
8.32% 636/1330 |
-13.59% 1351/1466 |
-4.42% 1482/1822 |
| 2020 | 47.41% 197/1250 |
6.34% 43/1028 |
28.46% 103/1067 |
3.48% 980/1164 |
4.28% 854/1184 |
| 2019 | 29.96% 492/1092 |
27.06% 363/754 |
-7.66% 570/804 |
5.75% 137/850 |
4.75% 784/918 |
| 2018 | -23.77% 300/834 |
- - |
- - |
- - |
-18.91% 659/691 |
| 2017 | 18.33% 208/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.03% 274/605 |
- - |
- - |
- - |
- - |
| 2015 | 34.15% 63/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华安中证细分医药ETF联接A VS. 长安沪深300非周期A(740101) |